highly significantP < 0.0001
Serum GSH-PX activity increased in all Ef026-treated groups after 8 weeks, with group IV displaying a highly significant enhancement ( P < 0.0001) compared to the control ( Fig. 1 B). By the trial’s conclusion, group III also exhibited markedly higher GSH-PX activity than the control ( P < 0.01).